US Patent

US10385341 — Compositions for modulating SOD-1 expression

Composition of Matter · Assigned to Biogen MA Inc · Expires 2035-04-01 · 9y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compositions that modulate SOD-1 expression, which can be used to treat or prevent amyotrophic sclerosis (ALS).

USPTO Abstract

Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).

Drugs covered by this patent

Patent Metadata

Patent number
US10385341
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-04-01
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Biogen MA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.